Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
Sign Up to like & getrecommendations! Published in 2021 at "Kidney international"
DOI: 10.1016/j.kint.2021.03.019
Abstract: Vadadustat is an investigational hypoxia-inducible factor prolyl hydroxylase inhibitor that increases endogenous erythropoietin production, and has been shown to decrease hepcidin levels, ameliorate iron restriction, and increase hemoglobin concentrations in anemic patients with chronic kidney… read more here.
Keywords: chronic kidney; kidney disease; mice; iron ... See more keywords
Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2021.795214
Abstract: Background: Vadadustat is a novel drug for treating anemia patients with chronic kidney disease (CKD), but its effect and safety remain uncertain. This study aimed to summarize the evidence for vadadustat in the treatment of… read more here.
Keywords: safety; certainty evidence; evidence; anemia patients ... See more keywords